Breakthrough Weight Loss Results: Novo Nordisk’s Wegovy Pill
Novo Nordisk recently announced impressive clinical trial results for its oral version of Wegovy. The results, released on Wednesday, showed that the pill delivered an average weight loss of 16.6%, matching the effectiveness of its blockbuster injection. This revelation sent the company’s shares soaring by 5.4% in morning trading.
The once-daily pill, which is currently under FDA review, is expected to receive a decision by the end of the year. If approved, it would become the first oral GLP-1 treatment for obesity. Remarkably, one-third of the study participants lost 20% or more of their body weight during the 64-week trial, demonstrating the pill’s potential to broaden access to weight-loss treatments.
This breakthrough comes at a time when Novo Nordisk is facing increasing competition from Eli Lilly in the rapidly expanding obesity drug market. If approved, the company has plans to manufacture the pill entirely in the United States, a move that responds to the Trump administration’s pressure for domestic pharmaceutical production.
For more details, read the full story on CNBC.